2. Linjakumpu T, Hartikainen S, Klaukka T, Veijola J, Kivelä SL, Isoaho R. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol 2002;55:809–817.
4. Korean Diabetes Association. Diabetes fact sheet in Korea 2022. Korean Diabetes Association; 2022.
5. Kwon HS. Prevalence and treatment status of diabetes mellitus in Korea. J Korean Med Assoc 2023;66:404–407.
6. Noh J. 2023 Clinical practice guidelines for diabetes: recommendations for pharmacological treatment of type 2 diabetes. J Korean Diabetes 2023;24:127–134.
7. Moon MK. 2023 Clinical practice guidelines for diabetes. J Korean Diabetes 2023;24:120–126.
8. Kim JH, Lee SH. Polypharmacy in Geriatrics and Beers Criteria. Korean J Fam Pract 2020;10:407–417.
10. Peron EP, Ogbonna KC, Donohoe KL. Antidiabetic medications and polypharmacy. Clin Geriatr Med 2015;31:17–27.
11. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128.
12. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–357.
14. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial. Lancet 2019;394:121–130.
15. Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34:535–542.
16. Valencia WM, Florez H. Pharmacological treatment of diabetes in older people. Diabetes Obes Metab 2014;16:1192–1203.
18. Shin EC. Educational strategies for insulin injection therapy in elderly diabetic patients. J Korean Diabetes 2018;19:101–105.
19. Lee GY. Education for insulin injection in elderly diabetic patients. J Korean Diabetes 2022;23:201–205.
20. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007;5:345–351.
21. Yoon JL. Appropriate pharmacotherapy in elderly patients. J Korean Med Assoc 2005;48:24–33.
23. Austin RP. Polypharmacy as a risk factor in the treatment of type 2 diabetes. Diabetes Spectr 2006;19:13–16.
24. Kumar A, Kumar S. Problems regarding polypharmacy in elderly in Indian population. Int J Pharm Res Int 2021;33:1113–1118.
25. Al-Musawe L, Torre C, Guerreiro JP, et al. Polypharmacy, potentially serious clinically relevant drug-drug interactions, and inappropriate medicines in elderly people with type 2 diabetes and their impact on quality of life. Pharmacol Res Perspect 2020;8:e00621.
26. Fillit HM, Rockwood K, Young JB. Multidimensional geriatric assessment. Brocklehurst’s textbook of geriatric medicine and gerontology. 8th ed. Elsevier; 2016. p. 213–219.
27. Halter JB, Ouslander JG, Studenski S, et al. Principles of geriatric assessment. Hazzard’s geriatric medicine and gerontology. 7th ed; 2017. p. 157–170.
28. Sergi G, De Rui M, Sarti S, Manzato E. Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use? Drugs Aging 2011;28:509–518.
31. Rollason V, Vogt N. Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist. Drugs Aging 2003;20:817–832.
32. Page AT, Potter K, Clifford R, Etherton-Beer C. Deprescribing in older people. Maturitas 2016;91:115–134.
33. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med 2015;175:827–834.
35. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616–631.
36. Evert AB, Franz MJ. American Diabetes Association guide to nutrition therapy for diabetes. 3rd ed. American Diabetes Association; 2017.
37. Kim SY. Management of diabetes in the elderly. J Korean Diabetes 2022;23:128–132.